Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBRETTO-531
2019-001978-28Phase 3Active
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Medullary Thyroid Cancer (MTC) comparing Selpercatinib with Physician's choice: cabozantinib or vandetanib (2 arms). Primary endpoint: Progression-free survival by blinded independent committee review. Started Dec 2019; status: active.
02
Drugs
selpercatinibcabozantinibvandetanib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on 2019-001978-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001978-28.